Simply Wall St has raised its fair value estimate for Biocon to ₹429.67 from ₹416.53, reflecting a shift in peer valuation cues and a greater emphasis on margin improvement plans. The updated model incorporates a lower revenue growth assumption of 14.01% and a reduced net profit margin of 10.73%, while the forward P/E multiple applied to projected earnings increased to 45.01 times from 35.56 times and the discount rate edged down to 13.21% from 13.45%. The revision follows recent analyst actions on peer Bio Rad, where RBC Capital, Citi, and Wells Fargo raised price targets, highlighting that the market is willing to assign higher multiples when there is visibility on execution, even in a tough macro environment. However, Wells Fargo's Equal Weight stance on Bio Rad underscores that execution risk and external headwinds may limit further valuation expansion for companies like Biocon.
Bio-Rad Laboratories IncPeer Bio-Rad's price target raises and Equal Weight stance are used as valuation cues for Biocon, not directly affecting Bio-Rad.
